Research
Energy balance
Most adverse events (AEs) associated with incretin-based therapies (IBTs) are mild or moderate and mainly occur during dose escalation.
Clinicians should monitor patients for mild to moderate AEs, especially during dose increases.
StrongSupportsmedium confidence
Most AEs were mild or moderate and mainly occurred during dose escalation.
Why this rating
Based on a systematic review involving over 400,000 participants.
Source
Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects
Robert F. Kushner et al. · Obesities · 2025
DOI 10.3390/obesities5020029
systematic_review · n=400000Cited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gastrointestinal adverse events (AEs) are common with incretin-based therapies (IBTs), with placebo-subtracted incidences of 5–39% for nausea, −7–39% for diarrhea, 2–31% for constipation, 0–26% for vomiting, and 2–20% for abdominal pain.Strong
- Quality of life outcomes generally showed improvements with incretin-based therapies (IBTs).Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →